Wall Street Underwhelmed After Third Wave Reports 43-Percent Increase in Q2 Revenues | GenomeWeb

Investors in Third Wave Technologies yawned Tuesday after the company posted a 43-percent jump in total revenues during the second quarter.

Shares in the Madison, Wis., pharmacogenomics company settled to just above $4 through most of Wednesday after reaching a high of $4.30 soon after Third Wave released its second-quarter earnings Tuesday morning.

Despite Third Wave’s positive earnings, the stock failed to reach the heights it reached two months ago, after a change in top management sent shares soaring to within pennies of their 52-week high of $5.48.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.